Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. May 25, 2022; 11(3): 86-95
Published online May 25, 2022. doi: 10.5527/wjn.v11.i3.86
Published online May 25, 2022. doi: 10.5527/wjn.v11.i3.86
Reno protective role of amlodipine in patients with hypertensive chronic kidney disease
Georgi Abraham, Department of Nephrology, MGM Healthcare, Nelson Manickam Road, Aminjikarai, Chennai 6300028, India
A Almeida, PD Hinduja Hospital and Medical Research Center, Almeida, A (reprint author), PD Hinduja, Hinduja Clin, Dept Med, Nephrol Sect, 2209 Veer Savarkar Marg, Bombay 400016, Maharashtra, Mumbai 400016, India
Kumar Gaurav, Mohammed Yunus Khan, Usha Rani Patted, Medical Affairs, Dr. Reddys Labs, Hyderabad 500016, Telangana, India
Maithrayie Kumaresan, Medical Affairs, Madras Medial Mission Hospital, Chennai 600037, India
Author contributions: Khan MY, Patted UR, and Gaurav K developed the concept and drafted the manuscript; All authors reviewed the manuscript and gave final approval.
Conflict-of-interest statement: Khan MY, Patted UR and Gaurav K are employees of Dr. Reddy’s Laboratories and may own stock. Abraham G, Almeida A, Kumaresan M are members of the advisory board for Dr. Reddy’s Laboratories.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mohammed Yunus Khan, MD, Medical Affairs, Dr. Reddys Labs, 7-1, 27, Ameerpet Road, Leelanagar, Ameerpet, Hyderabad 500016, Telangana, India.
Received: May 28, 2021
Peer-review started: May 28, 2021
First decision: July 31, 2021
Revised: August 23, 2021
Accepted: April 2, 2022
Article in press: April 2, 2022
Published online: May 25, 2022
Processing time: 360 Days and 23.6 Hours
Peer-review started: May 28, 2021
First decision: July 31, 2021
Revised: August 23, 2021
Accepted: April 2, 2022
Article in press: April 2, 2022
Published online: May 25, 2022
Processing time: 360 Days and 23.6 Hours
Core Tip
Core Tip: Amlodipine (ALM) is a powerful, well-tolerated, and safe anti-hypertensive agent widely used alone or as a key component of combination therapy for hypertension in chronic kidney disease (CKD). Its effectiveness in reducing blood pressure has proven benefits in cardiovascular event reduction and progression of renal disease. Overall, ALM emerges as the drug of choice in comparison to the newer calcium channel blockers in terms of its effectiveness and potency in BP lowering in CKD patients.